Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
<strong>Objective </strong>To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination. <br><strong> Design </strong>Observational cohort study. <br><strong> Setting </strong>Comm...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022
|
| _version_ | 1797107282461327360 |
|---|---|
| author | Ayoubkhani, D Bermingham, C Pouwels, KB Glickman, M Nafilyan, V Zaccardi, F Khunti, K Alwan, NA Walker, AS |
| author_facet | Ayoubkhani, D Bermingham, C Pouwels, KB Glickman, M Nafilyan, V Zaccardi, F Khunti, K Alwan, NA Walker, AS |
| author_sort | Ayoubkhani, D |
| collection | OXFORD |
| description | <strong>Objective </strong>To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination.
<br><strong>
Design </strong>Observational cohort study.
<br><strong>
Setting </strong>Community dwelling population, UK.
<br><strong>
Participants </strong>28 356 participants in the Office for National Statistics COVID-19 Infection Survey aged 18-69 years who received at least one dose of an adenovirus vector or mRNA covid-19 vaccine after testing positive for SARS-CoV-2 infection.
<br><strong>
Main outcome measure </strong>Presence of long covid symptoms at least 12 weeks after infection over the follow-up period 3 February to 5 September 2021.
<br><strong>
Results </strong>Mean age of participants was 46 years, 55.6% (n=15 760) were women, and 88.7% (n=25 141) were of white ethnicity. Median follow-up was 141 days from first vaccination (among all participants) and 67 days from second vaccination (83.8% of participants). 6729 participants (23.7%) reported long covid symptoms of any severity at least once during follow-up. A first vaccine dose was associated with an initial 12.8% decrease (95% confidence interval −18.6% to −6.6%, P<0.001) in the odds of long covid, with subsequent data compatible with both increases and decreases in the trajectory (0.3% per week, 95% confidence interval −0.6% to 1.2% per week, P=0.51). A second dose was associated with an initial 8.8% decrease (95% confidence interval −14.1% to −3.1%, P=0.003) in the odds of long covid, with a subsequent decrease by 0.8% per week (−1.2% to −0.4% per week, P<0.001). Heterogeneity was not found in associations between vaccination and long covid by sociodemographic characteristics, health status, hospital admission with acute covid-19, vaccine type (adenovirus vector or mRNA), or duration from SARS-CoV-2 infection to vaccination.
<br><strong>
Conclusions </strong>The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days. Vaccination may contribute to a reduction in the population health burden of long covid, although longer follow-up is needed. |
| first_indexed | 2024-03-07T07:13:53Z |
| format | Journal article |
| id | oxford-uuid:6fc420a7-af16-4366-8a62-405218bbec5c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:13:53Z |
| publishDate | 2022 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:6fc420a7-af16-4366-8a62-405218bbec5c2022-07-21T14:58:52ZTrajectory of long covid symptoms after covid-19 vaccination: community based cohort studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6fc420a7-af16-4366-8a62-405218bbec5cEnglishSymplectic ElementsBMJ Publishing Group2022Ayoubkhani, DBermingham, CPouwels, KBGlickman, MNafilyan, VZaccardi, FKhunti, KAlwan, NAWalker, AS<strong>Objective </strong>To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination. <br><strong> Design </strong>Observational cohort study. <br><strong> Setting </strong>Community dwelling population, UK. <br><strong> Participants </strong>28 356 participants in the Office for National Statistics COVID-19 Infection Survey aged 18-69 years who received at least one dose of an adenovirus vector or mRNA covid-19 vaccine after testing positive for SARS-CoV-2 infection. <br><strong> Main outcome measure </strong>Presence of long covid symptoms at least 12 weeks after infection over the follow-up period 3 February to 5 September 2021. <br><strong> Results </strong>Mean age of participants was 46 years, 55.6% (n=15 760) were women, and 88.7% (n=25 141) were of white ethnicity. Median follow-up was 141 days from first vaccination (among all participants) and 67 days from second vaccination (83.8% of participants). 6729 participants (23.7%) reported long covid symptoms of any severity at least once during follow-up. A first vaccine dose was associated with an initial 12.8% decrease (95% confidence interval −18.6% to −6.6%, P<0.001) in the odds of long covid, with subsequent data compatible with both increases and decreases in the trajectory (0.3% per week, 95% confidence interval −0.6% to 1.2% per week, P=0.51). A second dose was associated with an initial 8.8% decrease (95% confidence interval −14.1% to −3.1%, P=0.003) in the odds of long covid, with a subsequent decrease by 0.8% per week (−1.2% to −0.4% per week, P<0.001). Heterogeneity was not found in associations between vaccination and long covid by sociodemographic characteristics, health status, hospital admission with acute covid-19, vaccine type (adenovirus vector or mRNA), or duration from SARS-CoV-2 infection to vaccination. <br><strong> Conclusions </strong>The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days. Vaccination may contribute to a reduction in the population health burden of long covid, although longer follow-up is needed. |
| spellingShingle | Ayoubkhani, D Bermingham, C Pouwels, KB Glickman, M Nafilyan, V Zaccardi, F Khunti, K Alwan, NA Walker, AS Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
| title | Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
| title_full | Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
| title_fullStr | Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
| title_full_unstemmed | Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
| title_short | Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
| title_sort | trajectory of long covid symptoms after covid 19 vaccination community based cohort study |
| work_keys_str_mv | AT ayoubkhanid trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT berminghamc trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT pouwelskb trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT glickmanm trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT nafilyanv trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT zaccardif trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT khuntik trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT alwanna trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT walkeras trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy |